Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:11/28/2014)... , Nov. 28, 2014 The market for ... reach 7.9 billion dollars in 2014 according to Kalorama ... existing equipment and growing incidence of disease are driving ... X-Ray and Digital X-Ray: World Market Analysis ... X-Ray: World Market Analysis can be obtained at: ...
(Date:11/28/2014)... ATLANTA , Nov. 28, 2014 ... (Alimera), a pharmaceutical company that specializes in the ... has entered into a Securities Purchase Agreement with ... pursuant to which Alimera will issue shares of ... price of approximately $50.0 million upon the satisfaction ...
(Date:11/27/2014)... , Nov. 27, 2014  Javon Bea Mercy ... 19, faculty and staff at Janesville Craig High School ... from Mercy Health System physicians and Janesville ... Fire Departments and the Janesville ... Care Program, dedicated to providing schools and other organizations ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 2Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 3
... Tissues at Well-Tolerated ... Doses, ... data from a phase 1 dose-escalation trial of XL765, a,novel small molecule ... proliferation, survival, and,resistance to chemotherapy and radiotherapy. The trial is being carried ...
... III clinical trial --, CHICAGO, May 31 ... the presentation of updated results from,a 482 patient, ... dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone (VAD). Results ... in the VcD arm as induction therapy and ...
Cached Medicine Technology:Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 2Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 3Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 4Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... Brosix is always making changes to ... with a more efficient, effective, and secure experience. Most ... , 1. The ability to setup local servers for ... better service customers around the globe. , 2. The ... large customers that require millions of users in one ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Diane Walder, one of South Florida’s top cosmetic dermatologists ... Ultrashape that is designed to help her patients reduce unwanted ... Ultrashape has been praised by patients as being permanent, painless, ... other types of external fat reduction. , “If you can ... , According to Dr. Walder, Ultrashape works by targeting subcutaneous ...
(Date:11/28/2014)... Minnesota (PRWEB) November 28, 2014 ... of the few insurance marketing organizations in the ... income and asset protection marketplace. Secura Consultants is ... partnership with Principal Financial Group, a leading global ... multiple ownership interests. With the ownership interest comes ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... The following is being,issued by the Democratic ... Marca Bristo, former Chair of the National Council ... held a conference call today in,advance of John ... on,Disability Issues in Columbus, Ohio. There is speculation ...
... results -, LAVAL, QC, July 25 /PRNewswire-FirstCall/ - ... will host a conference call on,Friday, August 8 at ... results. Labopharm will report its second quarter 2008 financial,results ... day., To access the conference call by telephone, ...
... Impaired immune response after antiretroviral therapy may be due ... -- A new study challenges the long-held belief that ... ability to restore itself after HIV patients are treated ... percent to 90 percent of HIV-infected drug users are ...
... July 25, 2008 The American Society for ... of endoscopy in the bariatric surgery patient. The rising ... success in surgical interventions led to a marked increase ... U.S., from 13,365 in 1998 to 102,794 in 2003. ...
... of jobs created in the medical field slowed in June, pharmaceutical companies ... June than in previous months. , ... Seattle, WA (PRWEB) July 25, ... slowed in June overall, pharmaceutical companies reported a different kind of slowdown ...
... -, CORONA, Calif., July 25 Watson,Pharmaceuticals, ... pharmaceutical,company, announced today that its subsidiary has commenced ... in the 40mg,strength from its Davie, Florida manufacturing ... days of marketing exclusivity for being the,first to ...
Cached Medicine News:Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: